Aptamer Group

Aptamer Group develops custom affinity binders through its Optimer® platform, offering next-generation aptamer alternatives to antibodies for life science applications. Its affinity engineers work with customers to address challenging targets and create binders tailored to specific performance requirements, from early discovery through clinical development. The company serves pharmaceutical, diagnostic and biotechnology organisations, supporting research, therapeutics, diagnostics and bioprocessing.

Optimer® binders are designed for high specificity, stability and manufacturability. In therapeutics, they can support drug development and targeted delivery, including work on targets that may be difficult for other approaches. For diagnostics and research, they enable detection in a range of assays. In bioprocessing, their stability and reusability can support purification and quality control at manufacturing scale. Aptamer Group also offers Optimer® binders for trial or licensing, with custom modifications to assist platform integration. Its services include custom development, assay support, biomarker discovery and partnerships, alongside application resources and customer case studies.